Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664329 | 0.91 | CNR1 (0.46) | KMT2ATDP1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL13664373 | 0.91 | POLB (0.46) | KMT2ATDP1MEN1MAPTPOLB | |
| SCHEMBL13664143 | 0.91 | POLB (0.46) | KMT2ATDP1MEN1MAPTPOLB | |
| SCHEMBL13664332 | 0.90 | L3MBTL1 (0.43) | CFTRKMT2ATDP1MEN1MAPT | |
| SCHEMBL13664349 | 0.90 | CNR1 (0.46) | KMT2ATDP1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL13664403 | 0.89 | L3MBTL1 (0.46) | KMT2ATDP1MEN1MAPTPOLB | |
| SCHEMBL13664372 | 0.89 | CNR1 (0.47) | CFTRTDP1MAPTPOLBGAA | |
| SCHEMBL13664347 | 0.89 | CNR1 (0.43) | CFTRKMT2ATDP1MEN1MAPT | |
| SCHEMBL13664334 | 0.88 | KDM4E (0.49) | KMT2ATDP1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL13664333 | 0.88 | MAPT (0.42) | KMT2ATDP1MEN1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | CFTR 1209/4885KMT2A 3722/4885TDP1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.